Search

everythinglearnresearchcommunity

for

Search:↓

Staphylococcus aureus affects immune responses and skin cells in atopic dermatitis, suggesting new treatment targets.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

People often have negative attitudes towards facial skin conditions, with vitiligo seen most positively and psoriasis viewed most negatively.

Recognizing and treating related skin conditions can improve atopic dermatitis management.

Atopic dermatitis significantly increases the risk of alopecia areata, especially in children.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

Understanding skin microbes and sebum can help manage atopic dermatitis and hair loss.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Probiotics significantly reduce the severity of atopic dermatitis.

Atopic dermatitis and alopecia areata have a major global socioeconomic impact, needing more research and better healthcare alignment.

Cromolyn sodium oleate gel is more effective and safer for treating atopic dermatitis than dexamethasone.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.

Patients with anxiety or depression report more severe alopecia areata.

Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.

Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.

Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

The improved EczemaNet more reliably and clearly identifies and assesses the severity of atopic dermatitis from photos.

Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.

Mesenchymal stem cells and their secretions might help treat chronic skin inflammation in atopic dermatitis.